Navigation Links
Dynatronics Receives 180-Day NASDAQ Extension
Date:12/10/2009

SALT LAKE CITY, Dec. 10 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced that following last month's panel hearing, NASDAQ granted Dynatronics a full 180-day extension for regaining compliance with the $1.00 minimum bid requirement.

"We are pleased the panel granted us the full 180-day extension we requested," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "This will allow time for the market to consider important positive announcements we have recently made as well as additional positive announcements expected during the extension period. We believe the good financial results from our year ended June 30, 2009 combined with the trend of five consecutive profitable quarters provide important momentum going into this extension period. We will also have the opportunity during the extension period to report our financial results for the quarter ending December 31, 2009. We trust these factors will all help us move toward regaining compliance with the NASDAQ requirement."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at http://www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and similar statements such as the statement regarding the opportunity to make future announcements and move toward regaining compliance with NASDAQ's minimum bid requirement. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2009.

SOURCE Dynatronics Corporation


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
2. Dynatronics Will Request Hearing With Nasdaq Regarding Listing Status
3. Dynatronics to Release First Quarter Results Friday, November 13, 2009; Conference Call Set for 1:30 p.m. ET
4. Dynatronics Announces Positive Financial Results for Quarter
5. Dynatronics Named Sole-Source Supplier to Benchmark Physical Therapy
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):